memo - Magazine of European Medical Oncology

, Volume 5, Issue 2, pp 101–104

The role of biomarkers in the choice of therapy in breast cancer

Authors

    • 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)Private Medical University Hospital Salzburg
  • Sigrun Ressler
    • 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)Private Medical University Hospital Salzburg
  • Richard Greil
    • 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)Private Medical University Hospital Salzburg
short review

DOI: 10.1007/s12254-012-0027-y

Cite this article as:
Mlineritsch, B., Ressler, S. & Greil, R. memo (2012) 5: 101. doi:10.1007/s12254-012-0027-y
  • 59 Views

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.

Keywords

Breast cancerBiomarkerPrognosticPredictive

Copyright information

© Springer-Verlag Wien 2012